unilife time magazine, page-35

Terry, I think you'll find significant groundwork has already been done over the past year or so. Various analysts here and Stateside initiated coverage in 09, (try Googling analyst reports), and some institutions are already on board via the recent placement. From what I understand part of the reason for NASDAQ was to build on the significant institutional nvestment interest that has been developing in the US following the purchase of IBS and the overall redomicilation process. Coverage will only get bigger and better from here on in.

As for Jeffrey Kraws 'doing his bit', he is a vastly experienced and respected biotech analyst whose reports on Bloomberg reach millions of viewers, so perhaps a little more credit where its due...I certainly would not underestimate his coverage.

Thanks for your post goldstandard. Interesting read. The whole healthcare situation in the US and the EU bodes well for Unilife.